A law office recently noted that it filed a securities class action lawsuit on behalf of shareholders of a pharmaceutical company after it received allegations of securities law violations.
Scott and Scott, Attorneys at Law, LLP, announced that a lawsuit was filed in the U.S. District Court for the District of Massachusetts against Vertex Pharmaceuticals Incorporated. This includes all shareholders who acquired interests in the company during the class period between May 7, 2012, and May 29, 2012.
The litigation alleged that the leaders of Vertex Pharmaceuticals violated the Securities Exchange Act of 1934. This is due to the company allegedly making a number of statements that may have been misleading or false regarding its products VX-809 and Kalydeco.
It is an option for shareholders to apply for the lead plaintiff position in the case, but any interested parties will need to file all of the necessary paperwork with the court by July 28, 2014. This is not a mandatory action by those who own interests in Vertex Pharmaceuticals, and these individuals still have the ability to remain absent class members in the case, collecting in the event of a financial return.
For any stockholders who have questions about the lawsuit, how their rights or interested may be affected and any other related questions, it is possible to discuss these matters with the law office. Michael Burnett is the best person to speak with, and he can be reached by email or telephone. Additional details are available on the law office's website.
Second lawsuit filed
Another law firm noted that it filed a class action lawsuit against the leaders at Vertex Pharmaceuticals in the same court for many of the aforementioned reasons.
Law office Brower Piven explained that the lawsuit focuses on the company's alleged misrepresentation of the positive aspects of both phase two results for Kalydeco and VX-809, which hurt its stock performance.
It is possible to also discuss matters related to the lawsuit with this law office. This can involve learning more about taking up the lead plaintiff position, or other details on how this litigation may affect shareholders. The best person to discuss these matters with is Charles Piven, and he can be reached by telephone or email. The law office's website also has further details available to interested parties.